dm+d
Unassigned
New Medicines
Metastatic ER-positive HER2-negative breast cancer - second or third-line monotherapy
Information
New molecular entity
Roche
Roche
Development and Regulatory status
Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Category
Next generation selective estrogen receptor degrader/down regulator (SERD) that fully blocks ER signalling with robust receptor occupancy regardless of ESR1 mutation status (mutations in the ESR1 gene are important mechanisms of resistance to hormone tx)
There are around 55,200 new breast cancer cases in the UK every year. About 80% of all breast cancers are ER-positive [2].
Metastatic ER-positive HER2-negative breast cancer - second or third-line monotherapy
Oral